As for intranasal glucagon (Baqsimi), which was first FDA approved in July 2019, out-of-pocket costs were lower than unmixed glucagon for commercially insured patients.

Fresenius Kabi announced today the availability in the United States of its Glucagon Emergency Kit, an FDA-approved and cost-effective alternative to ...